Galapagos Investor Relations Material
Latest events
Q1 2025
Galapagos
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Galapagos NV
Access all reports
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises four Phase 2 programs, three Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Key slides for Galapagos NV
Q2 2024
Galapagos NV
Q4 2024
Galapagos NV
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
GLPG
Country
🇳🇱 Netherlands